Important Innovations

  COVID Vaccines Very Close to Market                                             Source:  Moderna Hope For a COVID Weary World Moderna, headquartered in Cambridge, MA, is seeking US, EU and UK emergency authorization for their COVID vaccine.  The vaccine has proved to be 94% effective.  The company adds it has no serious side effects. Highly Effective More than 1.5 million people have died from COVID.  Moderna says the vaccine is 100% effective in preventing severe cases of COVID.  It also works across demographic groups, including age, gender, ethnicity and race. Second COVID Vaccine Close to Market This is the second vaccine that is now under review for emergency authorization.  The other vaccine was developed by Pfizer and its German biotech partner BioNTech.  That vaccine is 95%.  Both the Pfizer and the Moderna vaccines could be on the market within two weeks.  Both vaccines were developed with a new technology called messenger RNA (mRNA).  Moderna says it will have 20 million do

Another $472 Million in Funds from US Government Source:  Moderna Cambridge, MA Potentially Quick Vaccine Development and Delivery Cambridge, MA based Moderna just announced it has received an additional $472 million in funding from the US government's Biomedical Advanced Research and Development Authority (BARDA).  That brings the total from BARDA to support the development of Moderna's novel COVID vaccine to $955 million. mRNA Moderna is the first pharma company in the US to begin human trials on a COVID vaccine.  Tomorrow, July 27th, a Phase 3 study  involving 30,000 participants will get underway with Moderna collaborating with the National Institute of Allergy and Infectious Diseases.  Moderna's vaccine candidate uses synthetic messenger RNA (mRNA) to help the body immunize against the virus. Potential Quick Delivery Moderna says it can deliver 500,000 doses of the vaccine per year and possibly 1 billion doses per year starting in 2021.  Experts say thei